Plain-English translation of NCT05756777 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether combining with either or can safely treat acute myeloid leukemia (AML) that has come back or stopped responding to other treatments. These are targeted medications designed to work against specific genetic mutations found in your cancer cells. The study will help doctors find the right dose and understand how well this combination works.
Many people with relapsed or refractory AML have limited treatment options and poor outcomes. This medication combination targets two specific genetic mutations at the same time, which may be more effective than treating one mutation alone.
You likely qualify if…
You likely don't qualify if…
You would take one of two drug combinations (either plus , or plus ) by mouth every day in 28-day cycles. You would visit the study center regularly for blood tests, check-ups, and monitoring to see how the treatment is working and check for side effects. The study is still recruiting participants, so the exact number of visits and total duration would be discussed with the research team.
AI-generated summary from trial data · Jun 26, 2026 · Not medical advice
United States